Guerrero David, Balen Enrique, Martínez-Peñuela José María, García-Foncillas Jesús, Larrinaga Begoña, Caballero María Cristina, Herrera Javier, Lera José Miguel
Centro de Investigación Biomédica. Servicio Navarro de Salud. Pamplona, Navarra, España.
Med Clin (Barc). 2005 Apr 2;124(12):441-6. doi: 10.1157/13073216.
Currently, colon cancer is a leading cause of cancer death world-wide. It progresses according to three molecular pathways, named suppressor, mutador and methylator. Microsatellite instability is a hallmark of the lack of reparation, of DNA mismatches and it characterizes a subset of colon tumors (unstable tumors, MSI). MSI-H patients (high degree of microsatellite instability) seem to share clinico-pathological differences with MSS (microsatellite stable) and MSI-L (low degree of microsatellite instability) patients. In this study, associations between high degree of microsatellite instability and pathological (location, mucinous content, differentiation grade, stages T3N0, stages II and III) and clinical features (response to chemotherapy, disease-free survival and overall survival) were evaluated.
117 patients with sporadic colon cancer were classified into two populations (MSS/MSI-L and MSI-H) by using PCR and electrophoresis of seven microsatellites, according to the National Cancer Institute recommendations.
MSI-H tumors tended to be located in the right colon (p = 0.022) and were of mucinous histologic type (p = 0.04). No differences in disease-free survival and overall survival between group of stage II and III patients with MSS/ MSI-L and corresponding ones with MSI-H colon cancer were found (p = 0.54, p = 0.37, respectively). Conversely, MSI-H patients with stage II colon cancer had a favourable prognosis (p = 0.027). Nevertheless, response to 5-fluorouracil (5-FU) and leucovorin was similar in MSS/ MSI-L and MSI-H groups (p = 0.38).
MSI-H patients are characterized by certain pathological features; those MSI-H patients with a stage II seem to have a better prognosis than MSS/ MSI-L patients.
目前,结肠癌是全球癌症死亡的主要原因之一。它按照三种分子途径进展,分别称为抑制型、突变型和甲基化型。微卫星不稳定性是DNA错配修复缺陷的标志,它是一部分结肠肿瘤(不稳定肿瘤,MSI)的特征。MSI-H患者(微卫星高度不稳定)似乎与MSS(微卫星稳定)和MSI-L(微卫星低度不稳定)患者在临床病理方面存在差异。在本研究中,评估了微卫星高度不稳定与病理特征(位置、黏液含量、分化程度、T3N0期、II期和III期)及临床特征(化疗反应、无病生存期和总生存期)之间的关联。
根据美国国立癌症研究所的建议,通过对七个微卫星进行PCR和电泳,将117例散发性结肠癌患者分为两组(MSS/MSI-L和MSI-H)。
MSI-H肿瘤倾向于位于右半结肠(p = 0.022),且为黏液组织学类型(p = 0.04)。在II期和III期的MSS/MSI-L组患者与相应的MSI-H结肠癌患者之间,未发现无病生存期和总生存期存在差异(分别为p = 0.54,p = 0.37)。相反,II期结肠癌的MSI-H患者预后良好(p = 0.027)。然而,MSS/MSI-L组和MSI-H组对5-氟尿嘧啶(5-FU)和亚叶酸的反应相似(p = 0.38)。
MSI-H患者具有某些病理特征;那些II期的MSI-H患者似乎比MSS/MSI-L患者预后更好。